Who are mg sulphate's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): Cordarone, zonisamide low dose group, Losartan/amlodipine or losartan/hydrochlorothiazide, Lyrica, Lercanidipine/enalapril fixed combination, flunarizine and/or pregabalin.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/mg-sulphate.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-15 · How we verify

mg sulphate — Competitive Intelligence Brief

mg sulphate (mg sulphate) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Calcium channel blocker. Area: Cardiovascular, Obstetrics.

phase 3 Calcium channel blocker Calcium channels Cardiovascular, Obstetrics Small molecule Live · refreshed every 30 min

Target snapshot

mg sulphate (mg sulphate) — Ain Shams University. Magnesium sulphate works by blocking calcium channels in the body, which helps to relax muscles and improve blood flow.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
mg sulphate TARGET	mg sulphate	Ain Shams University	phase 3	Calcium channel blocker	Calcium channels
Cordarone	AMIODARONE	Pfizer	marketed	Antiarrhythmic	sodium channels, potassium channels, calcium channels	1985-01-01
zonisamide low dose group	zonisamide low dose group	Eisai Korea Inc.	marketed	Anticonvulsant / Antiepileptic agent	Sodium channels, calcium channels, carbonic anhydrase
Losartan/amlodipine or losartan/hydrochlorothiazide	Losartan/amlodipine or losartan/hydrochlorothiazide	Yokohama City University Medical Center	marketed	Angiotensin II receptor blocker combination (ARB + calcium channel blocker or ARB + thiazide diuretic)	Angiotensin II type 1 receptor (AT1R); L-type voltage-gated calcium channels (amlodipine) or sodium-chloride cotransporter (hydrochlorothiazide)
Lyrica	Pregabalin	Pfizer Inc.	marketed	Anticonvulsant, analgesic	alpha-2-delta subunit (auxiliary subunit of voltage-gated calcium channels)
Lercanidipine/enalapril fixed combination	Lercanidipine/enalapril fixed combination	Meir Medical Center	marketed	Calcium channel blocker / ACE inhibitor combination	L-type voltage-gated calcium channels; Angiotensin-converting enzyme (ACE)
flunarizine and/or pregabalin	flunarizine and/or pregabalin	Taipei Veterans General Hospital, Taiwan	marketed	["Calcium Channel Blocker", "Anticonvulsant"]	["L-type calcium channels", "alpha2-delta subunit of voltage-gated calcium channels"]

Recent regulatory actions (last 90 days)

2026-02-24 — Lyrica · FDA · approved · US · Pfizer Inc.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

2026-11-02 — Lyrica · 10022447 · Method of Use · US
2026-11-02 — Lyrica · 8945620 · Formulation · US
2026-11-02 — Lyrica · 9144559 · Formulation · US
2027-05-02 — Lyrica · 9144559*PED · Compound · US
2027-05-02 — Lyrica · 10022447*PED · Compound · US
2027-05-02 — Lyrica · 8945620*PED · Compound · US

Sponsor landscape (Calcium channel blocker class)

Shenzhen Ausa Pharmed Co.,Ltd · 2 drugs in this class
Boryung Pharmaceutical Co., Ltd · 2 drugs in this class
Ain Shams University · 1 drug in this class
Bioprojet · 1 drug in this class
Bristol-Myers Squibb · 1 drug in this class
GlaxoSmithKline · 1 drug in this class
Handok Inc. · 1 drug in this class
Hasten Biopharmaceutical Co., Ltd. · 1 drug in this class
Hospital de Clinicas de Porto Alegre · 1 drug in this class
Laboratorios Richmond S.A.C.I.F. · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). mg sulphate — Competitive Intelligence Brief. https://druglandscape.com/ci/mg-sulphate. Accessed 2026-05-15.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab